CSTONE PHARMA-B (02616.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Nov25

Chi-Med's Sugemalimab Approved for Use in NSCLC Patients with Specific Genetic Features

04:05

Nov18

Yang Jianxin Increased Holdings in CStone Pharmaceuticals

11:23

Nov14

00:02

Nov13

Yang Jianxin Increased Holdings of Chi-Med Pharmacy By 100,000 Shares

11:22

Nov7

CStone Pharmaceuticals to Showcase CS2015 at ACAAI Annual Scientific Meeting

00:14

Nov4

CStone Pharmaceuticals' CS2009 Combination Therapy Clinical Trial for Advanced Solid Tumors Approved

00:01

Schedules & Filings

Schedules

Filings

Aug14

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 27.06 M, Net Income -147.86 M, EPS -0.1149

Mar27

Earning Release(CST)

FY2024 Q4 Earning Release (HKD) Revenue 81.41 M, Net Income -56.87 M, EPS -0.0445

Sep20

Earning Release(CST)

FY2024 Q2 Earning Release (HKD) Revenue 136.55 M, Net Income 8.435 M, EPS 0.0053

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change